Compare Omnicom Group Inc. (OMC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Omnicom Group Inc. vs 10X Genomics Inc — how do they compare? Omnicom Group Inc. trades at $76.03 (market cap $20.97B), while 10X Genomics Inc trades at $82.37 (market cap $10.07B). The key difference: Omnicom Group Inc. is far larger — about 2.1× 10X Genomics Inc's market cap, and Omnicom Group Inc. pays a 4.19% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Omnicom Group Inc. for 63 Days and 10X Genomics Inc for 92 Days on average.
| OMC | TXG | |
|---|---|---|
Market Cap | $20.97B | $10.07B |
Volume | 2,092,899 | 5,657,286 |
Sector | Media | Health |
52-Week High | $88.94 | $97.74 |
52-Week Low | $67.27 | $11.48 |
Typical Hold Time | 63 Days | 92 Days |
Enterprise Value | $29.05B | $9.59B |
Dividend Yield | 4.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Omnicom Group (OMC) trades at $74.87, down 0.31% on the day, with a bearish technical outlook. The stock shows mixed fundamentals with strong revenue growth to $17.27B in 2025 but negative net income of -$54.5M. Recent business developments include significant new billings of $3.3B in H1 2026 and leadership recognition in Gartner reports. Analyst consensus is mixed with 32% buy ratings but a $100.50 price target suggesting 34% upside potential.
OMC presents a value opportunity with attractive valuation metrics (P/S 0.86) and dividend yield, though recent earnings misses and high P/E ratio of 206.62 raise concerns. Key risks include advertising market volatility and debt levels, while catalysts include AI integration and post-merger synergies from the Interpublic acquisition.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
